DOCSLIB.ORG

Supplemental Figure 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Figure 1 Supplemental Figure 1 A AICDA APOBEC1 APOBEC2 APOBEC3A APOBEC3B 1.2 ● * ● ● ● ● ● 6 ● ● 1.0 ● ● 3 ● ● 1.5 ● ● 3 5 ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● 0.8 ● ● ● ● ● ● 4 ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 2 ● ● ● ● ● ● ● ● ●● 1.0 ● ● ● ● ● ● 2 ● ● ● ● ● ● ● ● ● ● ● ● ● 0.6 ● ●● ● ●● ● ●● ● ●● ● ● ● 3 ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ●● ● ● ● ● ● Log2 (TPM+1) ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● 0.4 ●● ● 2 ●●● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● 1 ● ● ●● ● ● ● 0.5 ● ● ●● ● 1 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ●● ●●● ● ● ● ●● ● ● ● ● ● 1 ● ● ● ● ●● ● 0.2 ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ●●● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ●● ●●●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ●●●● ● ● ●● ● ● ● ● ●●● ● ● ● ● ● ●● ●●● ● ● ● ● ●● ●●● ●●● ● ● ● ● ● ●● ● ● ●● ● ●● ● ●●●●● ●● ●● ● ● ● ●●● ●●●●● ● ● ● ● ●● ● ● ● ●● ●●●● ●● ● ●●● ● ●●● ● ● ● ● ●●●●● ● ● ● ● ●● ●● ● ●● ● ● ● ● ●●● ●● ●●● ●● ●● ● ● ● ●●●●●●●● ● ● ●● ● ●●●●● ●● ● ●●●● ●●● ● ● ●● ● ● ●● ● ● ●● ●● ● ● ● ● ● ● ●● ● ●● ●●●●● ● ● ● ● ● ●● ● ● ●●●● ●● ● ● ● ● ●● ●●●● ●● ● ●● ●●●●● ● ●● ●● ● ●● ● ● ●●●● ●●●●●● ● ● ●● ● ● ● ● ● ● ●●●● ●●●●● ● ● ● ●●●● ● ●●● ● ●● ●● ● ●●●●●●● ● ● ● ●●●●●●● ●● ●●● ● ●●● ● ● ● ● ●●●●●●● ● ●● ● ● ● ● ●● ●●●●●● ●●●●●●●●●● ●●●● ● ● ●● ● ●● ● ● ● ● ● ●● ● ● ● ●● ● ●● ●●●●● ●●● ●● ● ● ●●●● ●● ● ● ●●●●●●●● ● ● ●●●● ●●●●● ●●● ● ●● ● ● ●● ● ● ● ●●●●●●●●●●●●●●●●●●●●● ●● ● ● ● ●●●●● ●●●●● ● ●● ● ● ● ●●● ● ●●● ●●● ●●● ●● ● ● ● ● ●● ●●●●●●● ●●●●●● ●●●●● ●●●●●●● ●●● ●●●● ●●●●● ● ●●● ● ● ● ● ●●●●●●●●●●●●●●● ●●●●● ● ●●● ● ●●●●●●●● ●●●●● ●●● ●● ● ●●●● ● ●●● ● ●● ● ●●●●●● ● ●●●●●● ●●●●●●●●●●●●●●● ●●●●● ●●●●● ● ●● ● ● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ● ●●●● ●●● ●●● ● ●●●● ●● ●●●●●●● ● ●● ● ●● ●●● ●●● ● ● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●● ●●●●●●●●●● ●●●●●●●●● ●●●●●●●●●●●●●●●●●● ●● ● 0.0 ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● 0.0 ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● 0 0 0 LIHC LIHC LIHC LIHC LIHC (num(T)=369; num(N)=160)(num(T)=369; num(N)=160) (num(T)=369; num(N)=160) (num(T)=369; num(N)=160)(num(T)=369; num(N)=160) APOBEC3C APOBEC3D APOBEC3F APOBEC3G APOBEC3H 4 4 3.0 ● ● ● ● ● 6 ● ● 6 ● ● ● ● ● ● ● ● 2.5 ● 5 ● ● 5 ● ● 3 ● 3 ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 2.0 ● ● ● ● ● ● ● ● ● ● 4 4 ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 2 2 ● ● ● ● ● ● ● ● ●● ● ●● ●● ● ● ● ● ● ● ● ● ● ● 1.5 ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● 3 ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● 3 ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ●●● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● Log2 (TPM+1) ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ●● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● 1.0 ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● 2 ● ●●● ●● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ●● ● ●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ●● ● ● ● ●● ● ●● ● ●● ● ● ● ● ● ● ● ●● ● ● ●● ●● ● ●● ● ● 2 ●● ● ● ●● ● ●●● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ●● ● ●●● ● ● ●● ● ●● ●● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ● ●●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ●●● ●● ● ●● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● 1 ●● ● ●● ● 1 ● ● ●● ● ● ● ● ● ● ●●●●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●●● ● ●● ●● ● ●● ● ● ●● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ●● ● ●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●●● ● ● ●●● ●● ● ● ● ● ● ● ● ● ●● ●●●●● ● ● ● ● ●● ● ● ●● ● ● ● ●● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ●●● ● ● ●● ● ●●● ● ● ●● ●●●●●● ● ●● ● ●●● ●● ● ● ●● ● ●●● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●●● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ●●● ●●●● ● ● ● ● ● ● ● ● ● ● ●● ●●● ● ● ● ● ●●●●● ● ●● ● ● ●●● ● ● ●● ● ●● ● ● ● ● ●● ●● ● ● ● ●●●● ● ●● ●● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●● ● ●●● ● ● ● ● ●● ● ● ● ● ●● ● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ●●●● ● ● ● ● ● ● ●● ●●● ●●● ● ● ● ● ● ●●● ● ●● ● ● ●● ● ●●● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● 0.5 ●● ● ● ● ●● ●● ● ●● ● ●● ● ● ●● ● ● ● ● ●● ● ●●● ●● ● ●● ● ●● ● ● ●● ● ● ● ●● ●●● ●● ● ●●● ●● ● ●●●●●●● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● 1 ● ● ● ● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ●●● ● ●● ● ●● ● ● ● ● ● ●● ● ●● ● ● ●● ● ● ●● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ●● ● ●● ●● ● ● ● ● ●● ● ● ●● ●● ● ● ● ●● ● ● ● ●● ● ●● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ● ● ● ● ●●● ●●● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●●● ● ● ● ● ● ●● ●● ● ● ● ●● ● ● ●● ● ● ●● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ●● ●● ● ● ● ● ●● ● ● ●●● ● ● ● ● ●● ●● ● ●●● ● ●● ● ● ● ● ●● ● ● ● ● ● ● 1 ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●●● ● ● ● ● ● ● ●● ● ●● ●●● ● ● ● ● ● ● ● ● ● ●● ●●● ●●● ● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ●● ●● ● ● ● ● ● ●● ● ● ●● ●● ● ●● ●● ● ● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ●● ● ● ●● ● ● ●● ●● ● ● ● ● ●●●●●●● ●● ●● ●● ● ● ●●●●●●●●●● ● ●● ● ● ● ● ● ● ● ● ●● ●● ● ● ● ● ● ● ● ●● ●● ●● ● ● ● ● ●● ● ● ● ● ●● ● ● ● ● ● ● ● ●● ● ● ● ● ●● ● ●●●● ● ● ● ● ● ● ● ● ●● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ● ● ●● ● ●●● ● ● ● ● ● ● ● ● ● ● ●● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ● ● ●●● ● ● ● ●● ● ● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ● ●● ● ● ●●● ●● ● ●● ● ● ● ●● ● ● ● ● ● ●● ● ● ●● ●● ●●● ● ●●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ●● ● ● ● ●● ●● ● ● ●●● ●● ● ●● ● ● ● ● ● ● ● ● ● ● ● ● ●● ● ● ● ●● ●● ● ● ● ● ●● ● ● ● ●●● ● ● ● ● ●● ● ● ● ● ● ● ●● ● ● ● ●●● ● ●●●● ●● ● ● ●●● ● ●● ● ● ● ●●● ● ● ●● ● ● ● ●● ● ●● ● ● ● ● ● ● ● ● ● ●●● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● 0 0 0 ● 0.0 ●● ●●●●●● ● ●●●● LIHC LIHC LIHC LIHC LIHC (num(T)=369; num(N)=160) (num(T)=369; num(N)=160) (num(T)=369; num(N)=160) (num(T)=369; num(N)=160) (num(T)=369; num(N)=160) B GSE45436 Normal Tumor *** Log2 expression AICDA APOBEC1 APOBEC2 A3A A3B A3C A3D A3F A3G A3H C 40 Tumor * Normal s to Actin 30 l eve ion l 20 ess r p ex 10 ve i t a l e R 0 APOBEC3B APOBEC3C APOBEC3D APOBEC3F APOBEC3G APOBEC3H Supplemental Figure 2 A B Overall Survival Disease Free Survival Overall Survival Disease Free Survival Low APOBEC3A TPM Low APOBEC3A TPM Low APOBEC3B TPM 1.0 1.0 1.0 Low APOBEC3B TPM High APOBEC3A TPM High APOBEC3A TPM 1.0 High APOBEC3B TPM High APOBEC3B TPM Logrank p=0.8 al Logrank p=0.078 Logrank p=0.03 al al al v Logrank p=0.037 v HR(high)=0.95 HR(high)=0.76 v HR(high)=1.5 v 0.8 0.8 0.8 vi HR(high)=1.4 vi p(HR)=0.8 vi p(HR)=0.081 p(HR)=0.031 0.8 r vi r r p(HR)=0.038 n(high)=177 n(high)=177 n(high)=181 r n(low)=175 n(low)=175 n(low)=181 n(high)=181 0.6 n(low)=181 0.6 0.6 0.6 0.4 0.4 0.4 ercent su 0.4 ercent su ercent su ercent su P P P P 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0 20 40 60 80 100 120 0 20 40 60 80 100 120 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Months Months Months Months C D Overall Survival Disease Free Survival Overall Survival Disease Free Survival Low APOBEC3C TPM Low APOBEC3D TPM 1.0 Low APOBEC3C TPM 1.0 High APOBEC3C TPM 1.0 Low APOBEC3D TPM Logrank p=0.88 High APOBEC3C TPM High APOBEC3D TPM 1.0 High APOBEC3D TPM al al Logrank p=0.37 al Logrank p=1 al Logrank p=0.22 HR(high)=1 v v v HR(high)=0.87 HR(high)=1 v 0.8 0.8 p(HR)=0.87 0.8 HR(high)=0.83 vi vi vi 0.8 p(HR)=0.36 p(HR)=1 vi r r r n(high)=181 n(high)=181 n(high)=181 r p(HR)=0.22 n(low)=181 n(low)=181 n(low)=181 n(high)=181 0.6 0.6 0.6 n(low)=181 0.6 0.4 0.4 0.4 0.4 ercent su ercent su ercent su ercent su P P P P 0.2 0.2 0.2 0.2 0.0 0.0 0.0 0.0 0 20 40 60 80 100 120 0 20 40 60 80 100 120 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Months Months E F Months Months Overall Survival Disease Free Survival
Load more

Recommended publications
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Alyssa Lea MacMillan University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Virology Commons Recommended Citation MacMillan, Alyssa Lea, "Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance" (2013). Publicly Accessible Penn Dissertations. 894. https://repository.upenn.edu/edissertations/894 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/894 For more information, please contact [email protected]. Interactions Between APOBEC3 and Murine Retroviruses: Mechanisms of Restriction and Drug Resistance Abstract APOBEC3 proteins are important for antiretroviral defense in mammals. The activity of these factors has been well characterized in vitro, identifying cytidine deamination as an active source of viral restriction leading to hypermutation of viral DNA synthesized during reverse transcription. These mutations can result in viral lethality via disruption of critical genes, but in some cases is insufficiento t completely obstruct viral replication. This sublethal level of mutagenesis could aid in viral evolution. A cytidine deaminase-independent mechanism of restriction has also been identified, as catalytically inactive proteins are still able to inhibit infection in vitro. Murine retroviruses do not exhibit characteristics of hypermutation by mouse APOBEC3 in vivo. However, human APOBEC3G protein expressed in transgenic mice maintains antiviral restriction and actively deaminates viral genomes. The mechanism by which endogenous APOBEC3 proteins function is unclear. The mouse provides a system amenable to studying the interaction of APOBEC3 and retroviral targets in vivo.
    [Show full text]
  • Global Gene Expression Analysis of the Mouse Colonic Mucosa Treated
    BMC Cancer BioMed Central Research article Open Access Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate Rikako Suzuki1, Shingo Miyamoto2, Yumiko Yasui1, Shigeyuki Sugie1 and Takuji Tanaka*1 Address: 1Department of Oncologic Pathology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa 920-0293, Japan and 2Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Kyoto 606-8502, Japan Email: Rikako Suzuki - [email protected]; Shingo Miyamoto - [email protected]; Yumiko Yasui - y-yasui@kanazawa- med.ac.jp; Shigeyuki Sugie - [email protected]; Takuji Tanaka* - [email protected] * Corresponding author Published: 17 May 2007 Received: 10 July 2006 Accepted: 17 May 2007 BMC Cancer 2007, 7:84 doi:10.1186/1471-2407-7-84 This article is available from: http://www.biomedcentral.com/1471-2407/7/84 © 2007 Suzuki et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Chronic inflammation is well known to be a risk factor for colon cancer. Previously we established a novel mouse model of inflammation-related colon carcinogenesis, which is useful to examine the involvement of inflammation in colon carcinogenesis. To shed light on the alterations in global gene expression in the background of inflammation-related colon cancer and gain further insights into the molecular mechanisms underlying inflammation-related colon carcinogenesis, we conducted a comprehensive DNA microarray analysis using our model.
    [Show full text]
  • Table SII. Significantly Differentially Expressed Mrnas of GSE23558 Data Series with the Criteria of Adjusted P<0.05 And
    Table SII. Significantly differentially expressed mRNAs of GSE23558 data series with the criteria of adjusted P<0.05 and logFC>1.5. Probe ID Adjusted P-value logFC Gene symbol Gene title A_23_P157793 1.52x10-5 6.91 CA9 carbonic anhydrase 9 A_23_P161698 1.14x10-4 5.86 MMP3 matrix metallopeptidase 3 A_23_P25150 1.49x10-9 5.67 HOXC9 homeobox C9 A_23_P13094 3.26x10-4 5.56 MMP10 matrix metallopeptidase 10 A_23_P48570 2.36x10-5 5.48 DHRS2 dehydrogenase A_23_P125278 3.03x10-3 5.40 CXCL11 C-X-C motif chemokine ligand 11 A_23_P321501 1.63x10-5 5.38 DHRS2 dehydrogenase A_23_P431388 2.27x10-6 5.33 SPOCD1 SPOC domain containing 1 A_24_P20607 5.13x10-4 5.32 CXCL11 C-X-C motif chemokine ligand 11 A_24_P11061 3.70x10-3 5.30 CSAG1 chondrosarcoma associated gene 1 A_23_P87700 1.03x10-4 5.25 MFAP5 microfibrillar associated protein 5 A_23_P150979 1.81x10-2 5.25 MUCL1 mucin like 1 A_23_P1691 2.71x10-8 5.12 MMP1 matrix metallopeptidase 1 A_23_P350005 2.53x10-4 5.12 TRIML2 tripartite motif family like 2 A_24_P303091 1.23x10-3 4.99 CXCL10 C-X-C motif chemokine ligand 10 A_24_P923612 1.60x10-5 4.95 PTHLH parathyroid hormone like hormone A_23_P7313 6.03x10-5 4.94 SPP1 secreted phosphoprotein 1 A_23_P122924 2.45x10-8 4.93 INHBA inhibin A subunit A_32_P155460 6.56x10-3 4.91 PICSAR P38 inhibited cutaneous squamous cell carcinoma associated lincRNA A_24_P686965 8.75x10-7 4.82 SH2D5 SH2 domain containing 5 A_23_P105475 7.74x10-3 4.70 SLCO1B3 solute carrier organic anion transporter family member 1B3 A_24_P85099 4.82x10-5 4.67 HMGA2 high mobility group AT-hook 2 A_24_P101651
    [Show full text]
  • Deaminase-Independent Mode of Antiretroviral Action in Human and Mouse APOBEC3 Proteins
    microorganisms Review Deaminase-Independent Mode of Antiretroviral Action in Human and Mouse APOBEC3 Proteins Yoshiyuki Hakata 1,* and Masaaki Miyazawa 1,2 1 Department of Immunology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan; [email protected] 2 Kindai University Anti-Aging Center, 3-4-1 Kowakae, Higashiosaka, Osaka 577-8502, Japan * Correspondence: [email protected]; Tel.: +81-72-367-7660 Received: 8 December 2020; Accepted: 9 December 2020; Published: 12 December 2020 Abstract: Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 (APOBEC3) proteins (APOBEC3s) are deaminases that convert cytosines to uracils predominantly on a single-stranded DNA, and function as intrinsic restriction factors in the innate immune system to suppress replication of viruses (including retroviruses) and movement of retrotransposons. Enzymatic activity is supposed to be essential for the APOBEC3 antiviral function. However, it is not the only way that APOBEC3s exert their biological function. Since the discovery of human APOBEC3G as a restriction factor for HIV-1, the deaminase-independent mode of action has been observed. At present, it is apparent that both the deaminase-dependent and -independent pathways are tightly involved not only in combating viruses but also in human tumorigenesis. Although the deaminase-dependent pathway has been extensively characterized so far, understanding of the deaminase-independent pathway remains immature. Here, we review existing knowledge regarding the deaminase-independent antiretroviral functions of APOBEC3s and their molecular mechanisms. We also discuss the possible unidentified molecular mechanism for the deaminase-independent antiretroviral function mediated by mouse APOBEC3. Keywords: APOBEC3; deaminase-independent antiretroviral function; innate immunity 1.
    [Show full text]
  • 1 APOBEC-Mediated Mutagenesis in Urothelial Carcinoma Is Associated
    bioRxiv preprint doi: https://doi.org/10.1101/123802; this version posted April 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response Alexander P. Glaser MD, Damiano Fantini PhD, Kalen J. Rimar MD, Joshua J. Meeks MD PhD APG, DF, KJR, JJM: Northwestern University, Department of Urology, Chicago, IL, 60607 Running title: APOBEC mutagenesis in bladder cancer *Corresponding author: Joshua J. Meeks, MD PhD 303 E. Chicago Ave. Tarry 16-703 Chicago, IL 60611 Email: [email protected] Keywords (4-6): • Urinary bladder neoplasms • APOBEC Deaminases • Mutagenesis • DNA damage • Interferon Abbreviations and Acronyms: TCGA – The Cancer Genome Atlas ssDNA – single stranded DNA APOBEC –apolipoprotein B mRNA editing catalytic polypeptide-like GCAC – Genome Data Analysis Center MAF – mutation annotation format “APOBEC-high” – tumors enriched for APOBEC mutagenesis “APOBEC-low” – tumors not enriched for APOBEC mutagenesis 1 bioRxiv preprint doi: https://doi.org/10.1101/123802; this version posted April 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract: Background: The APOBEC family of enzymes is responsible for a mutation signature characterized by a TCW>T/G mutation. APOBEC-mediated mutagenesis is implicated in a wide variety of tumors, including bladder cancer. In this study, we explore the APOBEC mutational signature in bladder cancer and the relationship with specific mutations, molecular subtype, gene expression, and survival.
    [Show full text]
  • AID Downregulation Is a Novel Function of the DNMT Inhibitor 5-Aza-Deoxycytidine
    www.impactjournals.com/oncotarget/ Oncotarget, January, Vol. 5, No. 1 AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine Chiou-Tsun Tsai1, Pei-Ming Yang1, Ting-Rong Chern3, Shu-Hui Chuang1, Jung-Hsin Lin2,3,4, Lars Klemm5, Markus Müschen5 and Ching-Chow Chen1 1 Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan 2 School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan 3 Research Center for Applied Sciences, Academia Sinica, Taipei, Taiwan 4 Institute of Biomedical Science, Academia Sinica, Taipei, Taiwan 5 Department of Laboratory Medicine, University of California San Francisco, San Francisco, California Correspondence to: Ching-Chow Chen, email: [email protected] Keywords: AID, 5-aza-CdR, Zebularine, DNMT1 Received: August 23, 2013 Accepted: November 23, 2013 Published: November 25, 2013 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT: Activation-induced cytidine deaminase (AID) was originally identified as an inducer of somatic hypermutation (SHM) and class switch recombination (CSR) in immunoglobulin genes. However, AID can also cause mutations in host genes and contribute to cancer progression and drug resistance. In this study, molecular docking showed the interaction of free 5-aza-CdR and Zebularine (Zeb) with AID. However, only 5-aza-CdR-incorporated ssDNA bound to the active site of AID and inhibited AID expression through proteasomal degradation. 5-aza-CdR demonstrated cytotoxicity against AID-positive and -negative hematopoietic cancer cells.
    [Show full text]
  • Diversification of AID/APOBEC-Like Deaminases in Metazoa: Multiplicity
    Diversification of AID/APOBEC-like deaminases in PNAS PLUS metazoa: multiplicity of clades and widespread roles in immunity Arunkumar Krishnana, Lakshminarayan M. Iyera, Stephen J. Hollandb, Thomas Boehmb, and L. Aravinda,1 aNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894; and bDepartment of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany Edited by Anjana Rao, La Jolla Institute and University of California San Diego, La Jolla, CA, and approved February 23, 2018 (received for review November 30, 2017) AID/APOBEC deaminases (AADs) convert cytidine to uridine in viruses and retrotransposons through hypermutation of DNA during single-stranded nucleic acids. They are involved in numerous muta- reverse transcription (APOBEC3s) (21). genic processes, including those underpinning vertebrate innate and The deaminase superfamily displays a conserved β-sheet with adaptive immunity. Using a multipronged sequence analysis strategy, five β-strands arranged in 2-1-3-4-5 order interleaved with three we uncover several AADs across metazoa, dictyosteliida, and algae, α-helices forming an α/β-fold (the deaminase fold) (22), which it including multiple previously unreported vertebrate clades, and shares with JAB/RadC, AICAR transformylase, formate de- versions from urochordates, nematodes, echinoderms, arthropods, hydrogenase accessory subunit (FdhD), and Tm1506 superfamilies lophotrochozoans, cnidarians, and porifera. Evolutionary analysis sug- of proteins. The active site consists of two zinc (Zn)-chelating gests a fundamental division of AADs early in metazoan evolution into motifs, respectively typified by the signatures HxE/CxE/DxE at secreted deaminases (SNADs) and classical AADs, followed by diver- the end of helix 2 and CxnC (where x is any amino acid and n is ≥2) sification into several clades driven by rapid-sequence evolution, gene located in loop 5 and the beginning of helix 3 (Fig.
    [Show full text]
  • Insights Into the Structures and Multimeric Status of APOBEC Proteins Involved in Viral Restriction and Other Cellular Functions
    viruses Review Insights into the Structures and Multimeric Status of APOBEC Proteins Involved in Viral Restriction and Other Cellular Functions Xiaojiang S. Chen 1,2,3 1 Molecular and Computational Biology, Departments of Biological Sciences, Chemistry, University of Southern California, Los Angeles, CA 90089, USA; [email protected]; Tel.: +1-213-740-5487 2 Genetic, Molecular and Cellular Biology Program, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA 3 Center of Excellence in NanoBiophysics/Structural Biology, University of Southern California, Los Angeles, CA 90089, USA Abstract: Apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) proteins belong to a family of deaminase proteins that can catalyze the deamination of cytosine to uracil on single- stranded DNA or/and RNA. APOBEC proteins are involved in diverse biological functions, including adaptive and innate immunity, which are critical for restricting viral infection and endogenous retroelements. Dysregulation of their functions can cause undesired genomic mutations and RNA modification, leading to various associated diseases, such as hyper-IgM syndrome and cancer. This review focuses on the structural and biochemical data on the multimerization status of individual APOBECs and the associated functional implications. Many APOBECs form various multimeric complexes, and multimerization is an important way to regulate functions for some of these proteins at several levels, such as deaminase activity, protein stability, subcellular localization, protein storage Citation: Chen, X.S. Insights into and activation, virion packaging, and antiviral activity. The multimerization of some APOBECs is the Structures and Multimeric Status more complicated than others, due to the associated complex RNA binding modes.
    [Show full text]
  • A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2018 A High-Throughput Approach to Uncover Novel Roles of APOBEC2, a Functional Orphan of the AID/APOBEC Family Linda Molla Follow this and additional works at: https://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Linda Molla June 2018 © Copyright by Linda Molla 2018 A HIGH-THROUGHPUT APPROACH TO UNCOVER NOVEL ROLES OF APOBEC2, A FUNCTIONAL ORPHAN OF THE AID/APOBEC FAMILY Linda Molla, Ph.D. The Rockefeller University 2018 APOBEC2 is a member of the AID/APOBEC cytidine deaminase family of proteins. Unlike most of AID/APOBEC, however, APOBEC2’s function remains elusive. Previous research has implicated APOBEC2 in diverse organisms and cellular processes such as muscle biology (in Mus musculus), regeneration (in Danio rerio), and development (in Xenopus laevis). APOBEC2 has also been implicated in cancer. However the enzymatic activity, substrate or physiological target(s) of APOBEC2 are unknown. For this thesis, I have combined Next Generation Sequencing (NGS) techniques with state-of-the-art molecular biology to determine the physiological targets of APOBEC2. Using a cell culture muscle differentiation system, and RNA sequencing (RNA-Seq) by polyA capture, I demonstrated that unlike the AID/APOBEC family member APOBEC1, APOBEC2 is not an RNA editor. Using the same system combined with enhanced Reduced Representation Bisulfite Sequencing (eRRBS) analyses I showed that, unlike the AID/APOBEC family member AID, APOBEC2 does not act as a 5-methyl-C deaminase.
    [Show full text]
  • ADSSL1 Mutation Relevant to Autosomal Recessive Adolescent Onset Distal Myopathy
    RESEARCH ARTICLE ADSSL1 Mutation Relevant to Autosomal Recessive Adolescent Onset Distal Myopathy Hyung Jun Park, MD,1,2 Young Bin Hong, PhD,3 Young-Chul Choi, MD, PhD,2 Jinho Lee, MD,3 Eun Ja Kim, MD,3 Ji-Su Lee,4 Won Min Mo, MS,3 Soo Mi Ki, MS,4 Hyo In Kim,4 Hye Jin Kim,5 Young Se Hyun, PhD,5 Hyun Dae Hong,5 Kisoo Nam,6 Sung Chul Jung, MD, PhD,7 Sang-Beom Kim, MD, PhD,8 Se Hoon Kim, MD, PhD,9 Deok-Ho Kim, PhD,10 Ki-Wook Oh, MD,11 Seung Hyun Kim, MD, PhD,11 Jeong Hyun Yoo, MD, PhD,12 Ji Eun Lee, PhD,4,13 Ki Wha Chung, PhD,5 and Byung-Ok Choi, MD, PhD3,4,14 Objective: Distal myopathy is a heterogeneous group of muscle diseases characterized by predominant distal muscle weakness. A study was done to identify the underlying cause of autosomal recessive adolescent onset distal myopathy. Methods: Four patients from 2 unrelated Korean families were evaluated. To isolate the genetic cause, exome sequencing was performed. In vitro and in vivo assays using myoblast cells and zebrafish models were performed to examine the ADSSL1 mutation causing myopathy pathogenesis. Results: Patients had an adolescent onset distal myopathy phenotype that included distal dominant weakness, facial muscle weakness, rimmed vacuoles, and mild elevation of serum creatine kinase. Exome sequencing identified com- pletely cosegregating compound heterozygous mutations (p.D304N and p.I350fs) in ADSSL1, which encodes a muscle-specific adenylosuccinate synthase in both families. None of the controls had both mutations, and the muta- tion sites were located in well-conserved regions.
    [Show full text]
  • 1 Active Nuclear Import and Cytoplasmic Retention Of
    Active nuclear import and cytoplasmic retention of Activation Induced Deaminase Anne-Marie Patenaude1, Alexandre Orthwein1,2, Yi Hu1,3, Vanina A Campo1, Bodil Kavli3, Alejandro Buschiazzo4,5 and Javier M Di Noia1,2,6 1Institut de Recherches Cliniques de Montréal, 110 Av des Pins Ouest, Montréal, QC, H2W 1R7, Canada. 2Department of Microbiology and Immunology, Université de Montréal, Montréal, QC, Canada. 3Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Erling Skjalgssons gt. 1, DMF, 7006 Trondheim, Norway. 4Institut Pasteur de Montevideo, Unidad de Cristalografia de Proteinas, Montevideo, Uruguay. Mataojo 2020, Montevideo 11400, Uruguay. 5Institut Pasteur, Département de Biologie Structurale & Chimie, Paris, France. 6Department of Medicine, University of Montreal, Montreal, QC, Canada. Correspondence should be addressed to J.M.D email: [email protected] Tel: 1-514-987-5642, Fax: 1-514-987-5645. 1 Abstract The enzyme Activation Induced Deaminase (AID) triggers antibody diversification in B-cells by catalyzing deamination and consequently mutation of immunoglobulin genes. To minimize off-target deamination, AID is restrained by several regulatory mechanisms including nuclear exclusion, thought to be mediated exclusively by active nuclear export. Here we identify two other mechanisms involved in controlling AID subcellular localization. AID is unable to passively diffuse into the nucleus, despite its small size, its nuclear entry requiring active import mediated by a conformational nuclear localization sequence (NLS). We also identify a determinant for AID cytoplasmic retention in its C- terminus, which hampers diffusion to the nucleus, competes with nuclear import and is critical for maintaining the predominantly cytoplasmic localization of AID in steady-state conditions.
    [Show full text]